HK1130208A1 - Alpha-msh derivatives for the treatment of photodermatoses -msh - Google Patents

Alpha-msh derivatives for the treatment of photodermatoses -msh

Info

Publication number
HK1130208A1
HK1130208A1 HK09110252.3A HK09110252A HK1130208A1 HK 1130208 A1 HK1130208 A1 HK 1130208A1 HK 09110252 A HK09110252 A HK 09110252A HK 1130208 A1 HK1130208 A1 HK 1130208A1
Authority
HK
Hong Kong
Prior art keywords
msh
photodermatoses
alpha
treatment
derivatives
Prior art date
Application number
HK09110252.3A
Other languages
English (en)
Chinese (zh)
Inventor
Philippe Wolgen
Original Assignee
Clinuvel Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904745A external-priority patent/AU2006904745A0/en
Application filed by Clinuvel Pharmaceuticals Ltd filed Critical Clinuvel Pharmaceuticals Ltd
Publication of HK1130208A1 publication Critical patent/HK1130208A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK09110252.3A 2006-08-31 2009-11-04 Alpha-msh derivatives for the treatment of photodermatoses -msh HK1130208A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006904745A AU2006904745A0 (en) 2006-08-31 Method for Treatment of Photodermatoses
AU2007900862A AU2007900862A0 (en) 2007-02-21 Method for treatment of photodermatoses
PCT/AU2007/001276 WO2008025094A1 (en) 2006-08-31 2007-08-31 Method of treatment of photodermatoses

Publications (1)

Publication Number Publication Date
HK1130208A1 true HK1130208A1 (en) 2009-12-24

Family

ID=39135428

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09110252.3A HK1130208A1 (en) 2006-08-31 2009-11-04 Alpha-msh derivatives for the treatment of photodermatoses -msh

Country Status (17)

Country Link
US (1) US8334265B2 (xx)
EP (2) EP2056855B1 (xx)
AU (1) AU2007291886B2 (xx)
CA (1) CA2662163C (xx)
CY (1) CY1115804T1 (xx)
DK (2) DK2865422T3 (xx)
ES (2) ES2525476T3 (xx)
HK (1) HK1130208A1 (xx)
HU (2) HUE035074T2 (xx)
LU (1) LUC00062I2 (xx)
NL (1) NL300926I2 (xx)
NZ (1) NZ575133A (xx)
PL (2) PL2056855T3 (xx)
PT (2) PT2056855E (xx)
SI (2) SI2056855T1 (xx)
WO (1) WO2008025094A1 (xx)
ZA (1) ZA200901364B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113337A1 (en) * 2006-08-28 2010-05-06 Clinuvel Pharmaceuticals Limited Method for reducing incidence or rate of development of skin cancers and related conditions
EP2259794A1 (en) * 2008-02-22 2010-12-15 Clinuvel Pharmaceuticals Limited Method for treatment of photosensitivity and phototoxicity
ES2550160T3 (es) * 2008-03-27 2015-11-04 Clinuvel Pharmaceuticals Limited Terapia para el vitíligo
CN102458436B (zh) 2009-06-08 2015-06-03 帕拉丁科技公司 黑皮质素受体特异性肽
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
EP2487185A1 (en) * 2011-02-11 2012-08-15 Clinuvel Pharmaceuticals Limited Hexapeptide with improved activity in the repair of cellular DNA of dermal cells
US9371555B2 (en) 2012-06-01 2016-06-21 Concordia Laboratories Inc. Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin
EP3008184A1 (en) * 2013-06-13 2016-04-20 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
WO2015063102A1 (en) * 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in bullous disease
WO2015063099A1 (en) * 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in the treatment of hailey-hailey disease
EP3088417A1 (en) 2015-04-28 2016-11-02 Vallaurix Pte. Ltd. Pharmaceutical compound
EP3088418A1 (en) 2015-04-28 2016-11-02 Vallaurix Pte. Ltd. Pharmaceutical compound
AU2018215619A1 (en) * 2017-02-01 2019-08-08 Clinuvel Pharmaceuticals Ltd Alpha-MSH analogues used in the treatment of xeroderma pigmentosum
WO2021251452A1 (ja) 2020-06-10 2021-12-16 田辺三菱製薬株式会社 光線性皮膚疾患の予防又は治療剤
IL298952A (en) 2020-06-10 2023-02-01 Mitsubishi Tanabe Pharma Corp Prophylactic or therapeutic agent for porphyria
TW202214249A (zh) 2020-06-10 2022-04-16 日商田邊三菱製藥股份有限公司 紫質症之預防或治療劑

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
ATE84420T1 (de) 1986-02-03 1993-01-15 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5049547A (en) 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
EP1082463B1 (en) 1998-05-15 2007-01-03 Quark Biotech, Inc. Mechanical stress induced genes, expression products therefrom, and uses thereof
NZ534450A (en) 2002-02-26 2008-08-29 Arizona Board Of Regents Of Be Method of stimulation of melanin production and induction of skin tanning comprising administering alpha-MSH and exposing skin to UV irradiation
WO2006012667A1 (en) * 2004-08-04 2006-02-09 Clinuvel Pharmaceuticals Limited Methods of inducing melanogenesis in a subject.
AU2005291862B2 (en) * 2004-10-08 2010-07-08 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
US20100113337A1 (en) 2006-08-28 2010-05-06 Clinuvel Pharmaceuticals Limited Method for reducing incidence or rate of development of skin cancers and related conditions

Also Published As

Publication number Publication date
CY1115804T1 (el) 2017-01-25
NL300926I2 (nl) 2018-03-20
EP2056855B1 (en) 2014-09-17
PL2056855T3 (pl) 2015-04-30
EP2056855A4 (en) 2013-06-19
PT2865422T (pt) 2017-11-14
CA2662163C (en) 2015-11-24
HUE035074T2 (en) 2018-05-02
LUC00062I1 (xx) 2018-02-08
AU2007291886A1 (en) 2008-03-06
HUS1800006I1 (hu) 2018-05-02
US20100120668A1 (en) 2010-05-13
EP2056855A1 (en) 2009-05-13
WO2008025094A1 (en) 2008-03-06
SI2865422T1 (sl) 2017-12-29
EP2865422A1 (en) 2015-04-29
ES2646049T3 (es) 2017-12-11
ES2525476T3 (es) 2014-12-23
PT2056855E (pt) 2014-12-12
AU2007291886B2 (en) 2013-01-10
US8334265B2 (en) 2012-12-18
DK2056855T3 (en) 2014-12-15
LUC00062I2 (xx) 2018-03-28
ZA200901364B (en) 2010-06-30
DK2865422T3 (da) 2017-11-20
EP2865422B1 (en) 2017-10-18
PL2865422T3 (pl) 2018-01-31
CA2662163A1 (en) 2008-03-06
SI2056855T1 (sl) 2015-01-30
NZ575133A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
HUS1800006I1 (hu) Alfa-MSH származékok fotodermatózisok kezelésére
ZA200805877B (en) Pyridiazinone derivatives for tumour treatment
IL198847A (en) Process for making 2-imino-thiazolidine-4-on and several such histories
GB0624874D0 (en) Treatment
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
GB0600692D0 (en) Well treatment
IL196228A0 (en) 4-hydroxythiobenzamide derivatives of drugs
ZA201007362B (en) Conjugates for the treatment of mesothelioma
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
ZA200900230B (en) 4-hydroxythiobenzamide derivatives of drugs
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
PL380561A1 (pl) Sposób otrzymywania pochodnych antracyklin
IL226363A0 (en) Compounds and methods for treating cancer
GB0604460D0 (en) Treatment
IL194737A0 (en) 2-alkenyl-3-aminothiophene derivatives and processes for the preparation thereof
GB0602857D0 (en) The treatment of sialorrhoea
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
ZA200806180B (en) Benzoisoindole derivatives for the treatment of pain
GB0604114D0 (en) Combinations for the treatment of cancer
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0602858D0 (en) The treatment of sialorrhoea
IL194261A0 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
GB0625602D0 (en) Treatment of sialorrhoea
GB0610431D0 (en) Treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190903